Cardiol Therapeutics
Tracked across 2 events · 12 articles · First seen Aug 05, 2026 · Last active Sep 23, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Cardiol Therapeutics is the subject of the announcement, participating in the conference to present its clinical programs. This is a routine investor relations activity with no expected material impact on its stock.
Aug 05, 2026 · 6 articles
Tech
Cardiol Therapeutics Inc. announced on September 23, 2026 that its pivotal Phase III MAVERIC trial of CardiolRx for recurrent pericarditis reached its original 110-patient enrollment target ahead of end-of-September guidance. Following a blinded review showing…
Impact: The company is the central actor, achieving its Phase III enrollment target early and expanding the MAVERIC trial to up to 150 patients. The delayed topline timeline to mid-2027 and extended cash runway into Q1 2028 shape its near-term valuation.
Sep 23, 2026 · 6 articles
70
Cardiol Therapeutics achieved enrollment targetCardiol MAVERIC Phase III...
60
Cardiol Therapeutics delayed topline resultsCardiol MAVERIC Phase III...
40
United States — Food and Drug Administration granted Orphan Drug Designation Cardiol TherapeuticsCardiol MAVERIC Phase III...
ERGEN INTELLIGENCE
Track Cardiol Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard